Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Units to Offer Affymetrix's New DMET Services

NEW YORK (GenomeWeb News) — Affymetrix today launched its Drug Metabolizing Enzymes and Transporters early-access service program and announced that two units of Clinical Data would provide the services worldwide.
Affymetrix is initially launching the pharmacogenomics DMET panel as a service, which also is available through its clinical lab service in South San Francisco. The firm has said that it intends to offer the DMET panel as a catalogue product this year.
The panel was originally developed by ParAllele Bioscience and Eli Lilly and was scheduled to become commercially available in the third quarter of 2005. However, after Affy acquired ParAllele that year, the project was delayed as the company focused on launching a series of arrays for whole-genome genotyping.
Affy said that its panel is the “only product available with comprehensive coverage of all ADME drug metabolism biomarkers, including common and rare variations, insertions, deletions, copy number, triallelic SNPs, and pseudogenes.”
The alliance with Clinical Data allows its Cogenics and Epidauros Biotechnologie subsidiaries to offer the DMET service, with limited exclusive rights in Europe. Cogenics worked with Affy on development of the panel, which includes a total of 1,069 drug metabolism biomarkers.
Affy officials believe the service will be a major cost saver for the pharma industry, with adverse drug events costing $4 billion a year alone.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.